Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | NQO2 | P16083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3227968 | 0.81 | KCNH2 (0.32) | SLC2A1 | |
| SCHEMBL3230665 | 0.73 | HTR1A (0.34) | ALDH1A1MAPT | |
| SCHEMBL15875350 | 0.73 | ADRA1A (0.35) | MTNR1AMTNR1BHCRTR1HCRTR2SLC2A1 | |
| SCHEMBL3225974 | 0.69 | KDM4E (0.46) | MAPK1ALDH1A1MAPTCYP19A1NQO2 | |
| SCHEMBL3149562 | 0.69 | SLC2A1 (0.45) | MTNR1AMTNR1BSLC2A1HTR2C | |
| SCHEMBL17311898 | 0.68 | MTNR1A (0.36) | MTNR1AMTNR1BSLC2A1 | |
| SCHEMBL15875133 | 0.68 | PDE4A (0.33) | MTNR1AMTNR1BSLC2A1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3221898 | 0.68 | — | — | |
| SCHEMBL4590241 | 0.63 | CNR1 (0.33) | ALDH1A1MAPTCYP19A1NQO2 | |
| SCHEMBL15911203 | 0.63 | ADRA1A (0.49) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056502-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| EP-2125813-A2 | COMPOUNDS | Glaxo Group Limited (GB) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008116815-A2 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056502-A1 | COMPOUNDS | NRDC, NACA, NAA50 | MTNR1A 2151/4885MTNR1B 1480/4885HCRTR1 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.